Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CC-5013 (Lenalidomide) in AL Amyloidosis
NCT00091260Phase 2Completed
- Start
- Jan 2004
- Primary completion
- Jul 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide in amyloid light chain amyloidosis. Primary endpoints: Tolerability of CC-5013, Objective Hematologic Response Rate at 3 months and 2 more. Started Jan 2004; status: completed.
02
Drugs
lenalidomide
03
Conditions
amyloid light chain amyloidosis
Beyond the preview
Go deeper on NCT00091260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00091260.